modelInsulinAspart
Extends from Pharmacolibrary.Drugs.ATC.A.A10AD05.
Information
| name: | InsulinAspart | |
| ATC code: | A10AD05 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 0.2 | mg |
| volume of distribution: | 0.12 | L |
| clearance: | 1.2 | L/h |
| other parameters in model implementation | ||
Insulin aspart is a fast-acting human insulin analog used to improve glycemic control in adults and children with diabetes mellitus. It is approved for use in many countries and is commonly administered by subcutaneous injection immediately before meals.
Pharmacokinetics
Pharmacokinetic model parameters reported for healthy adult volunteers following single subcutaneous injection.
References
Rasmussen, CH, et al., & Colding-Jørgensen, M (2014). Insulin aspart pharmacokinetics: an assessment of its variability and underlying mechanisms. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 62 65–75. DOI:10.1016/j.ejps.2014.05.010 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24878388
Haahr, H, & Heise, T (2020). Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences. Clinical pharmacokinetics 59(2) 155–172. DOI:10.1007/s40262-019-00834-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31667789
Liu, H, et al., & Yu, Y (2025). Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study. Drug design, development and therapy 19 2863–2871. DOI:10.2147/DDDT.S500347 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40236299
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)